Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Atosiban

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 417,144Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel
    EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel

    11 Oct 2022

    // PHARMAINTELLIGENCE

    https://pink.pharmaintelligence.informa.com/PS147138/EU-Moment-of-Truth-For-Abaloparatide--Advanced-Therapy-TabCel

    PHARMAINTELLIGENCE
    11 Oct 2022
    Share Share
    Quince Presents Data Demonstrating Application of Bone-targeting Platform
    Quince Presents Data Demonstrating Application of Bone-targeting Platform

    12 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220912005365/en

    BUSINESSWIRE
    12 Sep 2022
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Tymlos (Abaloparatide)
    FDA Confirms Paragraph IV Patent Litigation for Tymlos (Abaloparatide)

    24 Aug 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-tymlos-abaloparatide-1661948708.pdf

    FDA
    24 Aug 2022
    Share Share
    Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA
    Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA

    11 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220811005185/en

    BUSINESSWIRE
    11 Aug 2022
    Share Share
    2 investment firms buy Radius, bone drug Tymlos for $890M
    2 investment firms buy Radius, bone drug Tymlos for $890M

    24 Jun 2022

    // Kevin Dunleavy FIERCEPHARMA

    https://www.fiercepharma.com/pharma/radius-health-bought-out-two-investment-firms-890-million

    Kevin Dunleavy FIERCEPHARMA
    24 Jun 2022
    Share Share